Its unique mechanism, which targets SNAP-25-mediated neurotransmitter release, differs fundamentally from that of CGRP antagonists, and may be especially advantageous in patients with comorbid muscle tension, allodynia, or insomnia, in which peripheral and central sensitization mechanisms are prominent [19]. Here, SNAP25 is linked to insomnia measurement.